UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report
(Date of earliest event reported) August 11, 2020
YIELD10
BIOSCIENCE, INC.
(Exact Name of
Registrant as Specified in Its Charter)
DELAWARE
(State or Other
Jurisdiction of Incorporation)
|
|
|
|
|
001-33133
|
|
04-3158289
|
|
(Commission File
Number)
|
|
(IRS Employer Identification
No.)
|
|
|
|
|
|
19
Presidential Way, Woburn, Massachusetts
|
|
01801
|
|
(Address of Principal
Executive Offices)
|
|
(Zip Code)
|
(617)
583-1700
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the
following provisions ( see
General
Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)).
Securities
registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock
|
YTEN
|
The Nasdaq Capital
Market
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company o
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. o
Item 2.02
Results Of Operations and Financial Condition.
On
August 11, 2020, Yield10 Bioscience, Inc. issued a press
release announcing the financial results for three and six months
ended June 30,
2020. A
copy of the press release is attached hereto as Exhibit 99.1.
This information, including Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Exchange Act, or
incorporated by reference in any filing under the Securities Act or
the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
Exhibit
|
|
|
|
No.
|
|
Description
|
|
|
|
Press Release dated August
11, 2020 announcing financial results for the three months ended
June 30, 2020
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
YIELD10
BIOSCIENCE, INC.
|
|
|
|
|
|
August 11, 2020
|
By:
|
/s/ Oliver P.
Peoples
|
|
|
|
Oliver P.
Peoples
|
|
|
|
President & Chief
Executive Officer
|
